$A — AVOID 📊 | 6 MONTHS THESIS

🧭 Conviction: MED Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. 🎯 FQ2 FY2026 (ends Apr) | reported May 27 | Rev $1.8B | Adj EPS $1.49 vs $1.41 🟢 | GAAP op margin 21.7% 💡 The market likely expected the beat; the real gap is that future growth must exceed the modest 0–2% revenue growth guidance. No evidence of a positive surprise on that front — guidance for next quarter is exactly in line ($1.48–$1.50). 🏢 Business Quality: 8/10 📊 Valuation: fair — trailing GAAP P/E 27.0x (vs historical median 26.3x, 58th percentile), reverse DCF implies 6.4% FCF growth, historical return base case -1.8%,... 🔮 Catalyst: Q3 FY2026 earnings (est. late Aug 2026) ⚖️ Avoid: solid company but full valuation and modest growth prospects yield an unattractive reward/risk for a 6-month long. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/A0711

🧭 Conviction: MED